Search
Search Results
-
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate...
-
Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
BackgroundGlucagon is secreted from pancreatic alpha cells in response to low blood glucose and increases hepatic glucose production. Furthermore,...
-
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Type 2 diabetes represents a growing challenge for global public health. Its prevalence is increasing worldwide, and, like obesity, it affects...
-
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
BackgroundAgonism at the receptor for the glucose-dependent insulinotropic polypeptide (GIPR) is a key component of the novel unimolecular...
-
Studies on prevalence of bovine gastrointestinal parasites (GIP) in Arghandab district of Kandahar province in Afghanistan
Helminth infections are one of the major constraints on livestock enterprises and cause great economic loss in Afghanistan. There is lack of data...
-
Changes in Gastric Inhibitory Polypeptide (GIP) After Roux-en-Y Gastric Bypass in Obese Patients: a Meta-analysis
This meta-analysis aimed to evaluate changes in GIP after RYGB in obese patients. We searched PubMed, EMBASE, and CENTRAL for relevant studies from...
-
-
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
BackgroundGlucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are the main incretin hormones, and be responsible for the insulinotropic...
-
-
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE....
-
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like...
-
-
Characterization of sporadic somatotropinomas with high GIP receptor expression
PurposeTo analyze the expression of glucose-dependent insulinotropic polypeptide receptor ( GIPR) in somatotropinomas specimens and compare clinical,...
-
Elevated levels of fasting serum GIP may be protective factors for diabetic retinopathy in type 2 diabetes mellitus
ObjectiveGlucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone which has been ascribed a positive role in cardiovascular...
-
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Aims/hypothesisTirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
-
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
ObjectivesTirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2...
